The European Commission reached its first deal to purchase future potential COVID-19 vaccines through a newly signed agreement with AstraZeneca. The deal includes the option to purchase 300 million doses and 100 million more on behalf of EU member states, should the vaccine prove to be effective. The deal would also allow the EU to donate vaccine doses to low-and middle-income countries or to redirect these doses to other European countries.
AstraZeneca’s vaccine candidate is currently in large-scale phase II/III clinical trials. The Commission has also been in negotiations with Sanofi-GSK and Johnson & Johnson on COVID-19 vaccine advance-purchasing deals.
Press release - European Commission